Abstract 2696: Genetic and pharmacologic evaluation of the ubiquitin ligase CBL-B as a small-molecule, tumor immunotherapy target

Gosling, J. A.; Rountree, Ryan B.; Taherbhoy, Asad M.; Wang, Chenbo; Cummins, Thomas; Cohen, Fred; Tanaka, Hiroko; Weiss, Dahlia R.; Cardozo, Mario; Karim, Christopher; Tan, May Loong; Juan, Joseph; Tenn-McClellan, Austin; Soly, Szerenke Kiss von; Sheung, Julie; Boyle, Kathleen; Dhamnaskar, Ketki; Kurylo, Katherine; Bruffey, Jilliane; McKinnell, Jennifer; Karr, Dane E.; Christianson, Andria; Vries, Anne-Renée Van der Vuurst de; Sivakumar, Pallavur V.; Gallop, Mark A.; Barsanti, Paul A.; Saha, Anjanabha; Bence, Neil; Zapf, Christoph W.

doi:10.1158/1538-7445.sabcs18-2696

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 As a RF ubiquitin ligase, the biological significance of CBLB enzymatic activity is a rapidly evolving area of research, with the discovery of its role in immunomodulation of the innate immune system published in 2014. 7,8,[45][46][47][48][49] This research activity highlights the need for small-molecule modulators of CBLB activity that can be used to better understand both the biology of this target in a research setting as well as those that can be translated into a clinical setting to improve disease outcomes. The experiments described in this article are the first published cell-free screen for modulators of CBLB enzymatic activity.…”

Section: Discussionmentioning

confidence: 99%